Taysha (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies Q3 2026 Earnings Call Transcript
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval
These 3 Risky Stocks Could Be Sitting on 100% Upside
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.